Kennedy Capital Management LLC Sells 24,196 Shares of AbbVie Inc. $ABBV

Kennedy Capital Management LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 27.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,967 shares of the company’s stock after selling 24,196 shares during the quarter. Kennedy Capital Management LLC’s holdings in AbbVie were worth $14,579,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the second quarter worth $26,000. Caitlin John LLC bought a new position in AbbVie in the 3rd quarter worth about $33,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie during the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC purchased a new stake in AbbVie during the 2nd quarter valued at about $39,000. Finally, Redmont Wealth Advisors LLC bought a new stake in AbbVie during the 3rd quarter valued at about $41,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple analyst takes and upgrades support upside expectations — AbbVie has a consensus “Moderate Buy” and RBC Capital started coverage with an Outperform rating and $260 price target, signaling analyst confidence in growth prospects. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Positive Sentiment: Early-stage clinical progress: AbbVie reported encouraging Phase 1 results for ABBV-295 and is advancing a risankizumab dosing study — both reinforce ongoing R&D momentum in immunology and targeted therapeutics. These readouts support longer-term growth optionality. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: Allergan Aesthetics (part of AbbVie’s portfolio) continues brand strength: a top New York provider was again named #1 by Allergan Aesthetics, a small near-term signal that the aesthetics business remains competitive. New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Mixed analyst valuation view: some models lift upside tied to immunology growth while others highlight competition risk; fair-value estimates have moved only slightly, implying limited near-term re-rating. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks
• Neutral Sentiment: Broader market and sector narratives (biotech growth resilience, psychiatric market expansion) provide context but are unlikely to move the stock materially absent company-specific catalysts. Josh Brown: Biotech growth stocks immune to disruption risk
• Negative Sentiment: Competitive pressure: UCB’s Bimzelx outperformed AbbVie’s Skyrizi in psoriatic arthritis, which raises near-term sales risk and may damp investor confidence in market share for a key immunology product. AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
• Negative Sentiment: Executive pay spike: reports that AbbVie’s CEO compensation rose above $30M may attract shareholder scrutiny on governance and costs. J&J, AbbVie CEOs See Pay Spike to More Than $30M

Analysts Set New Price Targets

Several brokerages have recently issued reports on ABBV. Morgan Stanley upped their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. UBS Group reduced their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Guggenheim restated a “buy” rating on shares of AbbVie in a report on Thursday. Citigroup cut their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Finally, Evercore reduced their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Stock Performance

Shares of ABBV traded down $1.38 during mid-day trading on Friday, hitting $223.99. 381,584 shares of the company traded hands, compared to its average volume of 7,064,824. The stock has a market cap of $396.05 billion, a price-to-earnings ratio of 95.09, a P/E/G ratio of 0.79 and a beta of 0.34. The stock has a 50-day moving average price of $224.52 and a two-hundred day moving average price of $224.48. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter last year, the company posted $2.16 earnings per share. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s payout ratio is presently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.